Exogenous Ghrelin Could Not Ameliorate 3,4-methylenedioxymethamphetamine-induced Acute Liver Injury in The Rat: Involved Mechanisms

Document Type : Research article

Authors

1 Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

2 Neurophysiology Research Center, Shahed University, Tehran, Iran.

3 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Immunology, School of Medicine, Tehran University of Medical Sciences Tehran, Iran

5 Department of Physiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

MDMA (3,4-methylenedioxymethamphetamine, ecstasy) is often abused by youth as a recreational drug. MDMA abuse is a growing problem in different parts of the world. An important adverse consequence of the drug consumption is hepatotoxicity of different intensities. However, the underlying mechanism of this toxicity has not been completely understood. Ghrelin is a gut hormone with growth hormone stimulatory effect. It expresses in liver, albeit at a much lower level than in stomach, and exerts a hepatoprotective effect. In this study, we investigated hepatotoxicity effect of MDMA alone and its combination with ghrelin as a hepatoprotective agent. MDMA and MDMA+ ghrelin could transiently increase serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) followed by tissue necrosis. However, they could significantly decrease liver tumor necrosis factor-a (TNF-α) in both treatment groups. Unexpectedly, in MDMA treated rats, Bax, Bcl-xl, Bcl-2, Fas, Fas ligand (Fas-L), caspase 8, cytochrome c, caspase 3 gene expression, and DNA fragmentation were nearly unchanged. In addition, apoptosis in MDMA+ ghrelin group was significantly reduced when compared with MDMA treated animals. In all,MDMA could transiently increase serum transaminases and induce tissue necrosis and liver toxicity. Ghrelin, however, could not stop liver enzyme rise and MDMA hepatotoxicity. MDMA hepatotoxicity seems to be mediated via tissue necrosis than apoptotic and inflammatory pathways. Conceivably, ghrelin as an anti-inflammatory and anti-apoptotic agent may not protect hepatocytes against MDMA liver toxicity.

Graphical Abstract

Exogenous Ghrelin Could Not Ameliorate 3,4-methylenedioxymethamphetamine-induced Acute Liver Injury in The Rat: Involved Mechanisms

Keywords

Main Subjects


References
(1) Montiel-Duarte C, Varela-Rey M, Osés-Prieto JA,
López-Zabalza MaJ, Beitia G, Cenarruzabeitia E and
Iraburu MaJ. 3, 4-Methylenedioxymethamphetamine 
352
Golchoobian R et al. / IJPR (2020), 19 (1): 343-354
(“Ecstasy”) induces apoptosis of cultured rat liver
cells. Biochim. Biophys. Acta (2002) 1588: 26-32.
(2) Hall A and Henry J. Acute toxic effects of
‘Ecstasy’(MDMA) and related compounds: overview
of pathophysiology and clinical management. Br. J.
Anaesth. (2006) 96: 678-85.
(3) Ellis A, Wendon J, Portmann B and Williams R.
Acute liver damage and ecstasy ingestion. Gut
(1996) 38: 454-8.
(4) Antolino-Lobo I, Meulenbelt J, van den Berg M
and van Duursen MB. A mechanistic insight into
3, 4-methylenedioxymethamphetamine (“ecstasy”)-
mediated hepatotoxicity. Vet. Q. (2011) 31: 193-205.
(5) Karch SB. A historical review of MDMA. Open
Forensic Sci. J. (2011) 4: 20-4.
(6) Dykhuizen R, Brunt P, Atkinson P, Simpson J and
Smith C. Ecstasy induced hepatitis mimicking viral
hepatitis. Gut (1995) 36: 939-41.
(7) Henry J, Jeffreys K and Dawling S. Toxicity and
deaths from 3, 4-methylenedioxymethamphetamine
(“ecstasy”). Lancet (1992) 340: 384-7.
(8) Milroy C, Clark J and Forrest A. Pathology of deaths
associated with” ecstasy” and” eve” misuse. J. Clin.
Pathol. (1996) 49: 149-53.
(9) Brauer LH and De Wit H. High dose pimozide does
not block amphetamine-induced euphoria in normal
volunteers. Pharmacol. Biochem. Behav. (1997) 56:
265-72.
(10) Caballero F, Lopez-Navidad A, Cotorruelo J and
Txoperena G. Ecstasy-induced brain death and
acute hepatocellular failure: multiorgan donor and
liver transplantation. Transplantation (2002) 74:
532-7.
(11) Garbino J, Henry J, Mentha G and Romand JA.
Ecstasy ingestion and fulminant hepatic failure:
liver transplantation to be considered as a last
therapeutic option. Vet. Hum. Toxicol. (2001) 43:
99-102.
(12) Liechti ME, Kunz I and Kupferschmidt H. Acute
medical problems due to Ecstasy use. Case-series
of emergency department visits. Swiss Med. Wkly.
(2005) 135: 652-7.
(13) Carvalho M, Carmo H, Costa VM, Capela JP,
Pontes H, Remião F, Carvalho F and de Lourdes
Bastos M. Toxicity of amphetamines: an update.
Arch. Toxicol. (2012) 86: 1167-231.
(14) Montiel-Duarte C, Ansorena E, López-Zabalza MJ,
Cenarruzabeitia E and Iraburu MJ. Role of reactive
oxygen species, glutathione and NF-κB in apoptosis
induced by 3, 4-methylenedioxymethamphetamine
(“Ecstasy”) on hepatic stellate cells. Biochem.
Pharmacol. (2004) 67: 1025-33.
(15) Stankevicius D, Ferraz-de-Paula V, Ribeiro A, Pinheiro
ML, de Oliveira APL, Damazo AS, Lapachinske
SF, Moreau RL, de Lima WT and Palermo-Neto
J. 3, 4-methylenedioxymethamphetamine (ecstasy)
decreases inflammation and airway reactivity in a
murine model of asthma. Neuroimmunomodulation
(2012) 19: 209-19.
(16) Connor TJ, Dennedy MC, Harkin A and Kelly
JP. Methylenedioxymethamphetamine-induced
suppression of interleukin-1β and tumour necrosis
factor-α is not mediated by serotonin. Eur. J.
Pharmacol. (2001) 418: 147-52.
(17) Camarasa J, Ros C, Pubill D and Escubedo E. Tumour
necrosis factor alpha suppression by MDMA is
mediated by peripheral heteromeric nicotinic
receptors. Immunopharmacol. Immunotoxicol.
(2010) 32: 265-71.
(18) Connor TJ, Harkin A and Kelly JP.
Methylenedioxymethamphetamine suppresses
production of the proinflammatory cytokine tumor
necrosis factor-α independent of a β-adrenoceptormediated increase in interleukin-10. J. Pharmacol.
Exp. Ther. (2005) 312: 134-43.
(19) Connor TJ, Kelly JP, McGee M and Leonard BE.
Methylenedioxymethamphetamine (MDMA;
Ecstasy) suppresses IL-1β and TNF-α secretion
following an in-vivo lipopolysaccharide challenge.
Life Sci. (2000) 67: 1601-12.
(20) Çetin E, Kanbur M, Çetin N, Eraslan G and
Atasever A. Hepatoprotective effect of ghrelin on
carbon tetrachloride-induced acute liver injury in
rats. Regul. Pept. (2011) 171: 1-5.
(21) Delporte C. Structure and physiological actions of
ghrelin. Scientifica (2013) 2013: 1-25.
(22) Kobeissy FH, Jeung JA, Warren MW, Geier JE and
Gold MS. Preclinical Study: Changes in leptin,
ghrelin, growth hormone and Neuropeptide‐Y after
an acute model of MDMA and methamphetamine
exposure in rats. Addict. Biol. (2008) 13: 15-25.
(23) Li Y, Hai J, Li L, Chen X, Peng H, Cao M and
Zhang Q. Administration of ghrelin improves
inflammation, oxidative stress, and apoptosis
during and after non-alcoholic fatty liver disease
development. Endocrine (2013) 43: 376-86.
(24) Moreno M, Chaves JF, Sancho-Bru P, Ramalho F,
Ramalho LN, Mansego ML, Ivorra C, Dominguez
M, Conde L and Millán C. Ghrelin attenuates
hepatocellular injury and liver fibrogenesis in
rodents and influences fibrosis progression in
humans. Hepatology (2010) 51: 974-85.
(25) Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson
S, Stoll LL, McCormick ML, Sigmund CD,
Tang C and Weintraub NL. Ghrelin inhibits
proinflammatory responses and nuclear factor-κB
activation in human endothelial cells. Circulation
(2004) 109: 2221-6.
353
Ghrelin Could Not Ameliorate Ecstasy-induced Liver Injury
(26) Dembinski A, Warzecha Z, Ceranowicz P, Konturek
P, Tomaszewska R, Stachura J and Konturek
S. Ghrelin attenuates the development of acute
pancreatitis in rat. J. Physiol. Pharmacol. (2003)
54: 561-74.
(27) Jacob A, Rajan D, Pathickal B, Balouch I, Hartman
A, Wu R, Zhou M and Wang P. The inhibitory
effect of ghrelin on sepsis-induced inflammation is
mediated by the MAPK phosphatase-1. Int. J. Mol.
Med. (2010) 25: 159-64.
(28) Yu A, Pei X, Sin T, Yip S, Yung B, Chan L, Wong C
and Siu P. Acylated and unacylated ghrelin inhibit
doxorubicin‐induced apoptosis in skeletal muscle.
Acta Physiol. (2014) 211: 201-13.
(29) Baldanzi G, Filigheddu N, Cutrupi S, Catapano F,
Bonissoni S, Fubini A, Malan D, Baj G, Granata R
and Broglio F. Ghrelin and des-acyl ghrelin inhibit
cell death in cardiomyocytes and endothelial cells
through ERK1/2 and PI 3-kinase/AKT. J. Cell Biol.
(2002) 159: 1029-37.
(30) Wang Z, Yang WL, Jacob A, Aziz M and Wang
P. Human ghrelin mitigates intestinal injury and
mortality after whole body irradiation in rats. PLoS
One (2015) 10: e0118213.
(31) Cerretani D, Bello S, Cantatore S, Fiaschi A,
Montefrancesco G, Neri M, Pomara C, Riezzo I,
Fiore C and Bonsignore A. Acute administration of
3, 4-methylenedioxymethamphetamine (MDMA)
induces oxidative stress, lipoperoxidation and
TNFα-mediated apoptosis in rat liver. Pharmacol.
Res. (2011) 64: 517-27.
(32) Aguirre N, Barrionuevo M, Ramírez MJ, Del
Río J and Lasheras B. α-Lipoic acid prevents 3,
4-methylenedioxy-methamphetamine (MDMA)-
induced neurotoxicity. Neuroreport (1999) 10:
3675-80.
(33) Jahromi MG, Nabavizadeh F, Vahedian J,
Nahrevanian H, Dehpour AR and Zare-Mehrjardi
A. Protective effect of ghrelin on acetaminopheninduced liver injury in rat. Peptides (2010) 31:
2114-7.
(34) Camargo CA, Madden JF, Gao W, Selvan RS and
Clavien P. Interleukin-6 protects liver against
warm ischemia/reperfusion injury and promotes
hepatocyte proliferation in the rodent. Hepatology
(1997) 26: 1513-20.
(35) Lin X, Liu X, Huang Q, Zhang S, Zheng L, Wei L,
He M, Jiao Y, Huang J and Fu S. Hepatoprotective
effects of the polysaccharide isolated from
Tarphochlamys affinis (Acanthaceae) against CCl
4-induced hepatic injury. Biol. Pharm. Bull. (2012)
35: 1574-80.
(36) Yu Z, Zhang L, Wu D and Liu F. Anti-apoptotic
action of zearalenone in MCF-7 cells. Ecotoxicol.
Environ. Safe. (2005) 62: 441-6.
(37) Beitia G, Cobreros A, Sainz L and Cenarruzabeitia E.
3, 4-Methylenedioxymethamphetamine (ecstasy)-
induced hepatotoxicity: effect on cytosolic calcium
signals in isolated hepatocytes. Liver (1999) 19:
234-41.
(38) Beitia G, Cobreros A, Sainz L and Cenarruzabeitia
E. Ecstasy-induced toxicity in rat liver. Liver
(2000) 20: 8-15.
(39) Giboney PT. Mildly elevated liver transaminase
levels in the asymptomatic patient. Am. Fam.
Physician. (2005) 71: 1105-10.
(40) Connor TJ, Kelly JP and Leonard BE. An assessment of the acute effects of the serotonin releasers
methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity
in rats. Immunopharmacology (2000) 46: 223-35.
(41) Dixit VD, Schaffer EM, Pyle RS, Collins GD,
Sakthivel SK, Palaniappan R, Lillard JW and Taub
DD. Ghrelin inhibits leptin-and activation-induced
proinflammatory cytokine expression by human
monocytes and T cells. J. Clin. Invest. (2004) 114:
57-66.
(42) Wu R, Dong W, Cui X, Zhou M, Simms HH,
Ravikumar TS and Wang P. Ghrelin downregulates proinflammatory cytokines in sepsis
through activation of the vagus nerve. Ann. Surg.
(2007) 245: 480-6.
(43) Pasparakis M, Alexopoulou L, Episkopou V and
Kollias G. Immune and inflammatory responses in
TNF alpha-deficient mice: a critical requirement
for TNF alpha in the formation of primary B cell
follicles, follicular dendritic cell networks and
germinal centers, and in the maturation of the
humoral immune response. J. Exp. Med. (1996)
184: 1397-411.
(44) Keane J. TNF-blocking agents and tuberculosis:
new drugs illuminate an old topic. Rheumatology
(2005) 44: 714-20.
(45) Strangfeld A, Listing J, Herzer P, Liebhaber A,
Rockwitz K, Richter C and Zink A. Risk of herpes
zoster in patients with rheumatoid arthritis treated
with anti–TNF-α agents. JAMA (2009) 301: 737-
44.
(46) Furst DE. The risk of infections with biologic
therapies for rheumatoid arthritis. Semin. Arthritis
Rheum. (2010) 39: 327-46.
(47) Boyle NT and Connor TJ. Methylenedioxymethamphetamine (‘Ecstasy’)-induced immunosuppression: a cause for concern? Br. J. Pharmacol. (2010)
161: 17-32.
(48) Taub R. Liver regeneration: from myth to
mechanism. Nat. Rev. Mol. Cell Biol. (2004) 5:
836-47.
354
Golchoobian R et al. / IJPR (2020), 19 (1): 343-354
(49) Bradham CA, Plümpe J, Manns MP, Brenner DA
and Trautwein C. I. TNF-induced liver injury. Am.
J. Physiol. Gastrointest. Liver Physiol. (1998) 275:
G387-G92.
(50) Schwabe RF and Brenner DA. Mechanisms of
liver injury. I. TNF-α-induced liver injury: role
of IKK, JNK, and ROS pathways. Am. J. Physiol.
Gastrointest. Liver Physiol (2006) 290: G583-G9.
(51) French JB, Bonacini M, Ghabril M, Foureau D and
Bonkovsky HL. Hepatotoxicity associated with the
use of anti-TNF-α agents. Drug Saf. (2016) 39:
199-208.
(52) Warren MW, Kobeissy FH, Liu MC, Svetlov SI,
Hayes RL, Gold MS and Wang KK. Ecstasy
toxicity: a comparison to methamphetamine and
traumatic brain injury. J. Addict. Dis. (2006) 25:
115-23.
(53) Cadet JL, Ordonez SV and Ordonez JV.
Methamphetamine induces apoptosis in
immortalized neural cells: Protection by the protooncogene, bcl-2. Synapse (1997) 25: 176-84.
(54) Bortolami M, Kotsafti A, Cardin R and Farinati F.
Fas/Fas-L system, IL-1β expression and apoptosis
in chronic HBV and HCV liver disease. J. Viral
Hepat. (2008) 15: 515-22.
(55) Da Silva DD, Carmo H, Lynch A and Silva E. An
insight into the hepatocellular death induced by
amphetamines, individually and in combination:
the involvement of necrosis and apoptosis. Arch.
Toxicol. (2013) 87: 2165-85.
(56) Pontes H, Sousa C, Silva R, Fernandes E, Carmo H,
Remião F, Carvalho F and Bastos ML. Synergistic
toxicity of ethanol and MDMA towards primary
cultured rat hepatocytes. Toxicology (2008) 254:
42-50.
(57) Schulze-Bergkamen H, Schuchmann M, Fleischer B
and Galle PR. The role of apoptosis versus oncotic
necrosis in liver injury: facts or faith? J. Hepatol.
(2006) 44: 984-93.